What is AIDX's market cap?

$2.39M, based on the Nov 5 close of $0.19.

Does 20/20 Biolabs pay a dividend?

No regular cash dividend has been paid in the last year.

How much of AIDX is sold short?

11.3K shares, 0.1% of float, as of Oct 15, 2026.

What sector is AIDX in?

Technology, in the Testing Laboratories industry.

NASDAQ · AIDXTechnologyTesting Laboratories

20/20 Biolabs, Inc. Common Stock (AIDX)

$0.1869−18.35%

Close Nov 5, 2026 · split-adjusted

Oct 30, 2026$0.21▼ 99.11% in range

Feb 19, 2026Low $0.21 · High $23.85Oct 30, 2026

What changed · written from our data

As of Nov 5, 2026

20/20 Biolabs closed at $0.19 on Nov 5, down 18.35%, within 0.0% of its lowest close since Feb 19. Volume of 523.8K shares was 2.51× its 20-day average (well above normal).

Split-adjusted performance: -45.6% over one month.

In the quarter ended Jun 30, 2026, revenue was $730.57K, with a net margin of -376.8%.

Short interest was 11.3K shares at the Oct 15 settlement, down 75.0% from the prior report (0.1% of float, 1.0 days to cover).

Market cap$2.4M12.8M shares

Revenue · quarter$730.6K—

Diluted EPS$-0.26—

P/E · TTM—

Net margin-376.8%Gross 41.7%

Dividend yieldNone

Range since Feb 190.19 – 23.85−99.2% from high

Volume523.8K2.51× 20-day avg

Volatility · 60d—Annualised

Short % of float0.1%1.0 days to cover

Net cash$4.5MCash $4.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −18.2%1M −45.6%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Testing Laboratories

Percentile among 3 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return +29.2%, revenue growth +8.3%, net margin −3.6%, P/E 30.0×.

Short interest

Details →

Shares short11.3K−75.0% vs prior

Days to cover1.0Settled Oct 15

% of float0.1%

Short vol. 10d36.8%of daily volume

Closest peers by size in Testing Laboratories

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
AIDX20/20 Biolabs	$0.1869	−18.35%	—	—	−376.8%	—	$2.4M
NEONeoGenomics	$16.49	−3.85%	+81.8%	+11.4%	−3.6%	—	$2.13B	Compare
ULSUL Solutions	$76.15	−4.49%	−23.4%	+5.1%	13.1%	30.0	$15.37B	Compare

News about 20/20 Biolabs

All news →

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial OpportunityGlobeNewswire Inc. · Aug 28, 2026▲ Positive 20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each MonthGlobeNewswire Inc. · Jun 22, 2026▲ Positive 20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational ProgressGlobeNewswire Inc. · Mar 31, 2026▲ Positive

Quick answers

What does 20/20 Biolabs do?: 20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
What is AIDX's market cap?: $2.39M, based on the Nov 5 close of $0.19.
Does 20/20 Biolabs pay a dividend?: No regular cash dividend has been paid in the last year.
How much of AIDX is sold short?: 11.3K shares, 0.1% of float, as of Oct 15, 2026.
What sector is AIDX in?: Technology, in the Testing Laboratories industry.

About 20/20 Biolabs

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

HQ: Rockville, MD14 employeesListed Feb 19, 20262020biolabs.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology